For example, in a phase II clinical trial using allogeneic whole‐cell vaccination, a canine melanoma cell line transfected with human gp100, killed by irradiation and intradermally administered to dogs with malignant melanoma, found objective evidence of tumour regression in 17.6% of cases, with dogs experiencing tumour control surviving significantly longer (337 days) than dogs having no response (95 days) [125]. The gene discussed is PMEL; the disease is melanoma.